# Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II)

> **NCT00668785** · PHASE2 · TERMINATED · sponsor: **Jumper, J. Michael, M.D.** · enrollment: 6 (actual)

## Conditions studied

- Proliferative Diabetic Retinopathy
- Macular Edema

## Interventions

- **DRUG:** ranibizumab

## Key facts

- **NCT ID:** NCT00668785
- **Lead sponsor:** Jumper, J. Michael, M.D.
- **Sponsor class:** INDIV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-03
- **Primary completion:** 2010-06
- **Final completion:** 2012-03
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Study was terminated due to low enrollment
- **Last updated:** 2019-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00668785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00668785, "Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00668785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*